Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Feb:103:214-216.
doi: 10.1016/j.ijid.2020.11.191. Epub 2020 Dec 2.

A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Sabeena Ahmed  1 , Mohammad Mahbubul Karim  1 , Allen G Ross  1 , Mohammad Sharif Hossain  1 , John D Clemens  1 , Mariya Kibtiya Sumiya  1 , Ching Swe Phru  1 , Mustafizur Rahman  1 , Khalequ Zaman  1 , Jyoti Somani  2 , Rubina Yasmin  3 , Mohammad Abul Hasnat  4 , Ahmedul Kabir  5 , Asma Binte Aziz  1 , Wasif Ali Khan  6
Affiliations
Randomized Controlled Trial

A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Sabeena Ahmed et al. Int J Infect Dis. 2021 Feb.

Abstract

Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.

Keywords: Bangladesh; COVID-19; Doxycycline; Ivermectin; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no known competing financial interests or personal relationships that could have appeared to influence the work described in this paper.

Figures

Figure 1
Figure 1
Cumulative viral recovery estimates in the overall study population.
See this image and copyright information in PMC

Comment in

References

    1. Alam M.T., Murshed R., Bhiuyan E., Saber S., Alam R., Robin R. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. J Bangladesh Coll Physic Surg. 2020;38:10–15. doi: 10.3329/jbcps.v38i0.47512. - DOI
    1. Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. 2020. "The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res, from https://www.ncbi.nlm.nih.gov/pubmed/32251768 (Caly et al. 2020), Apr 3. - PMC - PubMed
    1. Centers for Disease Control and Prevention . 2020. Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infection, Updated March 7, 2020. [Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-manageme... [accessed 17.11.2020]
    1. Chiu S.H., Lu A.Y. In: Ivermectin and Abamectin. Campbell W.C., editor. Springer-Verlag; New York, NY: 1989. Metabolism and tissue residues; pp. 131–143.
    1. Johns Hopkins University of Medicine COVID-19 . 2020. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University.https://coronavirus.jhu.edu/map.html (accessed 17.11.2020)

Publication types